
β-Adrenergic Blocking Agents. 11. Heterocyclic Analogs of Pronethalol [2-Isopropylamino-1-(2-naphthyl)ethanol]

M. S. Chodnekar, A. F. Crowther, W. Hepworth, R. Howe,* B. J. McLoughlin, A. Mitchell, B. S. Rao, R. P. Slatcher, L. H. Smith, and M. A. Stevens

Imperial Chemical Industries Limited, Pharmaceuticals Division, Alderley Park, Macclesfield, Cheshire, England. Received June 6, 1971

The synthesis and biological properties of further heterocyclic analogs of pronethalol (3) are reported. Examples are given in which the side chain is attached to the benzenoid part and to the heterocyclic part of a heterocyclic system. Many of the compounds have the pronethalol level of potency as β -adrenergic blocking agents. The most potent compounds contain features of the propranolol (4) type.

We have previously reported¹ the synthesis and β -adrenergic blocking potencies of a series of 1-(1,4-benzodioxan-2-yl)-(1) and 1-(chroman-2-yl)-2-aminoethanols (2) which contain features of both pronethalol (3)[†] and propranolol (4)[‡]. In this paper we report the synthesis and properties of further heterocyclic analogs of pronethalol.²⁻⁴



In Table I the side chain is always the same as it is in pronethalol (3), and examples are given where it is attached to the benzenoid part (5 to 21), and where it is attached to the heterocyclic part of a heterocyclic system (22 to 39). In Table II the substituents on N are varied.


The most general method used (A, eq 1, Scheme I) was reductive (NaBH₄) amination of a glyoxal.⁵ The side chain attached to the 2 or 3 positions of indole analogs (22-28 and 44-47) was always formed by reduction (LAH) of an intermediate glyoxylamide (B, eq 2).⁶ The indole analog 23 was obtained by removal (Na-NH₃) of the benzyl group from the indole N of 27. Several compounds were made by reduction (NaBH₄) of an intermediate amino ketone (C, eq 3).⁵ Compds 6 and 29 were prepared by reductive alkylation of an amino ketone with Me₂CO and NaBH₄ or Pt-H₂ (D, eq 4).⁵ Related routes gave 43 by reductive (Pt-H₂) alkylation of an amino alcohol with a ketone (eq 5) and 34

Scheme I

| RCOCHO $\xrightarrow{H_2NR_1}$ [RCOCH=NR ¹ $\xrightarrow{NaBH_4}$ RCOCH ₂ NHR ¹] $\xrightarrow{NaBH_4}$ RCHOHCH ₂ NHR ¹ | (1) |
|---|-----|
| RCOCONR ¹ R ² <u>LAH</u> RCHOHCH ₂ NR ¹ R ² | (2) |
| RCOCH ₂ NR ¹ R ² <u>NaBH₄</u> RCHOHCH ₂ NR ¹ R ² | (3) |
| $RCOCH_2NH_2 \xrightarrow{Me_2CO} [RCOCH_2N=CMe_2] \xrightarrow{NaBH_4} Or Pt-H_2$ | |
| RCHOHCH ₂ NH- <i>i</i> -Pr | (4) |
| RCHOHCH ₂ NH ₂ $\xrightarrow{R^1R^2CO}$ [RCHOHCH ₂ N=CR ¹ R ²] $\xrightarrow{Pt-H_2}$ RCHOHCH ₂ NHCHR ¹ R ² | (5) |

$$RCOCHN_2 \xrightarrow{Me_2CO + Pd - H_2} RCHOHCH_2NH-i-Pr$$

(6)



$$\begin{array}{c} \text{RCHOHCH}_{2}X \xrightarrow{\text{HNR}^{1}R^{2}} \left[\text{RCH} \xrightarrow{\text{O}} \text{CH}_{2} \right] \xrightarrow{\text{HNR}^{1}R^{2}} \\ \text{RCHOHCH}_{2}\text{NR}^{1}R^{2} \end{array}$$
(8)

by reductive (Pd-H₂) alkylation of a diazo ketone with Me_2CO (eq 6).⁵ Reductive (Pd-H₂) alkylation of the nitro alcohol 79 with Me_2CO gave 31 and 80; partial saturation of the isoquinoline and addition of the NH thus formed to the azomethine intermediate in the reductive alkylation would give 80 (eq 7). In method E (eq 8) a halohydrin was treated with an amine to give, *via* an oxirane, the desired amino alcohol.⁵ For 30 an intermediate oxirane 81, prepared by the action of dimethyloxosulfonium methylide on an aldehyde,⁷ was used in place of a halohydrin.

Compound 32 was obtained by treating either 2-acetoxyacetylquinoxaline (82) or 2- $(\alpha_{\beta}\beta$ -diacetoxyvinyl)quinoxaline (83) with *i*-PrNH₂ and then NaBH₄.³ These two intermediates were obtained by acetylation of the compound, which we regard as the polymer 84, obtained by treatment of 2-(D-arabino-tetrahydroxybutyl)quinoxaline with base.⁸

[†] Alderlin. ‡Inderal.

| Table I. RCHO Compound | R | Methods ^a | Form | Crystn solvent ^b | Mp,°C | Formula | Analyses | Infusion rate, µg/kg per min | % change in heart rate | % inhibition of tachycardia |
|---------------------------|---|--|-----------|---------------------------------------|---------|---|----------------------|---------------------------------|------------------------|--------------------------------|
| 5 | CH ₃ CH ₃ H | A ^c | Base | P(100) | 157-158 | C ₁₅ H ₂₂ N ₂ O | С, Н | 100 | 10 | 20 |
| 6 | | D ^d (Pt-H ₂) | HBr | H ₂ O + Me ₂ CO | 210 | C ₁₂ H ₁₈ BrN ₃ O ₂ | C, H; N ^e | 100 | 10 | 35 |
| 7 | | Α | Dipicrate | BuOH | 235-236 | C ₂₆ H ₂₄ N ₈ O ₁₅ | N | 100 ^f | 10 | 43 |
| 8 | OH N | A ^g | Oxalate | MeOH-EtOAc | 200–202 | $C_{16}H_{20}N_2O_6 \cdot 1.5H_2O$ | C, H, N | 50 | 12 | 53 |
| 9 | CH ₃ | A ^h | Tartrate | MeOH-EtOAc | 200 | $\mathrm{C_{19}H_{26}N_2O_8}\cdot\mathrm{H_2O}$ | H, N; C ⁱ | 25 | 4 | 82 |
| 10 | O N CH ₂ CH ₃ | A ^j | Tartrate | MeOH-EtOAc | 164 | $C_{20}H_{28}N_2O_8 \cdot 0.5H_2O_8$ | C, II, N | 100 | -18 | 90 |
| 11 | N CH ₂ CH ₂ CH=CH ₂ | A ^k | Tartrate | EtOH-EtOAc | 126 | $\mathrm{C_{21}H_{28}N_2O_8} \cdot 0.5\mathrm{H_2O}$ | C, H, N | 100 | 16 | 80 |
| 12 | O N (CH ₂) ₃ CH ₃ | A ¹ | Tartrate | EtOH-EtOAc | 123 dec | $C_{22}H_{32}N_2O_8 \cdot 0.5H_2O_8$ | С, Н, N | 200 | 29 | 58 |

| 13 | O N CH ₃ | A ^m | Oxalate | MeOH-EtOAc | 189 dec | $\mathbf{C_{17}H_{22}N_2O_6}\cdot\mathbf{H_2O}$ | С, Н, N | 500 | 0 | 12 |
|------------|------------------------------------|----------------|---------|-------------------------------|---------|---|-----------------|-----|-----|-----|
| 14 | | E | Base | EtOAc | 144–145 | C ₁₇ H ₂₀ N ₂ OS | C, H, N, S | 400 | -21 | Nil |
| 15 | | A ⁿ | Base | EtOAc | 108 | C ₁₃ H ₁₉ NO ₂ | C, H, N | 100 | -23 | 69 |
| 16 | CH ₂ O | A ^o | Oxalate | Et ₂ O | 188–190 | $C_{30}H_{44}N_2O_8$ | H, N; C | 100 | +5 | 19 |
| 17 | | С | Base | EtOAc | 93-94 | C ₁₂ H ₁₇ NO ₃ | C, H, N | 25 | +34 | 80 |
| 18 | | A ^q | Base | EtOAc | 105-106 | C ₁₄ H ₂₁ NO ₂ | C, H, N | 100 | 18 | 71 |
| 19 | | С | HCi | MeOH + Et ₂ O | 184-185 | C ₁₃ H ₂₀ CINO ₃ | C, H, Cl, N | 25 | -3 | 45 |
| 20 | | С | HCl | MeOH + EtOAc | 163–164 | C ₁₄ H ₂₂ CINO ₃ | C, H, CI, N | 100 | 14 | 54 |
| 2 1 | | A ^r | Oxalate | EtOH | 251 | $C_{36}H_{40}N_2O_8$ | С, Н | 100 | -13 | 44 |
| 22 | CH ₃ CH ₃ | B₂ | Base | C ₆ H ₆ | 126–127 | C ₁₅ H ₂₂ N ₂ O | С, Н, N | 400 | -32 | Nil |
| 23 | N H | See Expti | Base | P(80) | 134–136 | $C_{13}H_{18}N_2O$ | C, H, N | 50 | 0 | 35 |
| 24 | N CH ₃ | B ^t | Base | EtOAc | 114–115 | $C_{14}H_{20}N_2O$ | С, Н, N | 100 | +2 | 70 |

| Table I (Continued |
|--------------------|
|--------------------|

| Compound | R | Methods ^a | Form | Crystn solvent ^b | Mp,°C | Formula | Analyses | Infusion rate, μ g/kg per min | % change in heart rate | % inhibition of tachycardia |
|----------|--|------------------------|---------|-----------------------------|---------|--|----------------------|--------------------------------------|------------------------|-----------------------------|
| 25 | N CH ₂ CH ₃ | В | Base | EtOAc | 125-126 | C ₁₅ H ₂₂ N ₂ O | С, Н, N | 50 | 6 | 38 |
| 26 | (CH ₂) ₃ CH ₃ | В | Base | P(80) | 66-68 | C ₁₇ H ₂₆ N ₂ O | С, Н, N | 100 400 | 18 22 | Nil 11 |
| 27 | ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ | В | Base | EtOAc | 120 | $\mathrm{C}_{20}\mathrm{H}_{24}\mathrm{N}_{2}\mathrm{O}$ | C, H, N | 100 | 14 | Nil |
| 28 | NNC ₆ H ₅ | В | Base | P(80) | 110 | $C_{20}H_{24}N_2O$ | C, H, N | 200 | 14 | Nil |
| 29 | O N CH ₃ | D NaBH ₄ | Oxalate | MeOH-EtOAc | 176–178 | $\mathbf{C_{17}H_{22}N_2O_6}\cdot\mathbf{H_2O}$ | N; C, H ^u | 100 500 | +2 15 | Nil 16 |
| 30 | N CH ₃ O | See Exptl | Base | EtOAc | 152–154 | $C_{15}H_{20}N_2O_2$ | C, H, N | 50 | +24 | 68 |
| 31 | CH ₃ | See Exptl | Di-HCl | MeOH + EtOAc | 272–274 | C ₁₄ H ₂₄ Cl ₂ N ₂ O | C, H, Cl, N | 100 | +22 | 50 |
| 32 | N | See Exptl | Base | P(60) | 98–99 | C ₁₃ H ₁₇ N ₃ O | C, H, N | 50 | 0 | 93 |

| 33 | CH ₃ | E ^ν | Base | EtOAc + P(40) | 89–90 | $C_{14}H_{19}N_3O$ | C, H, N | 100 | +7 | 33 |
|-----|---|----------------|---------|-------------------------------|---------|---|--------------------------|-----------|-----------|-----------|
| 34 | SO ₂ C ₆ H ₄ CH ₃ | See Expti | Base | EtOAc + P(40) | 150–151 | $C_{20}H_{26}N_2O_4S$ | C, H, N, S | 50 200 | +7 +22 | Nil 17 |
| 35 | | A ^w | Base | P(80) | 108–109 | C ₁₃ H ₁₇ NO ₂ | C, H, N | 5 | +23 | 80 |
| 36A | | E ^x | Base | P(60) | 116-118 | C ₁₃ H ₁₉ NO ₂ | C, H, N | 10 | -1 | 80 |
| 36B | | E ^x | Base | P(40) | 85-86 | | у | 10 | +12 | 90 |
| 37 | | E ^z | Base | C ₆ H ₆ | 110 | C ₁₂ H ₁₇ NO ₃ | C, H, N | 10 | 0 | 63 |
| 38 | | Eaa | Oxalate | EtOH-EtOAc | 198–199 | $C_{20}H_{32}N_2O_6S_2$ | C, N, S; H ^{bb} | 200 | 8 | 16 |
| 39 | C s | Α | Base | EtOH-EtOAc | 193–194 | C 13H 18CINOS | C, H, N | 50 | +7 | 42 |


53

Adrenergic Blocking Agents. 11


^aMethods refer to Experimental Section. ^bP(40), P(60), P(80), and P(100) refer to petroleum ether bp 40-60°, bp 60-80°, bp 80-100°. and bp 100-120°. ^cCrude 2.3-dimethylindol-6-vlglvoxal obtd bv method F (dioxane) from 1-acetyl-2,3-dimethylindol-6-yl methyl ketone [W. Borsche and H. Groth, Justus Liebigs Ann. Chem., 549, 238 (1941)]. The 1-Ac group was removed by the condns used in method A. ^dCrude aminomethyl benzimidazol-2-on-5-yl ketone hydrobromide was obtd by method J from bromomethyl benzimidazol-2-on-5-yl ketone.¹³ ^eN: calcd, 13.3; found, 12.7. ^fAdministered as free base. ^gCrude 4-hydroxyquinolin-6-ylglyoxal hydrate obtd by method F (AcOH) from 4-hydroxyquinolin-6-yl methyl ketone.¹⁹ ^hCrude 1-methyl-4-quinolon-6-ylglyoxal hydrate obtd by method F (AcOH) from 49. iC: calcd, 53.3; found, 52.8. /Crude 1-ethyl-4-quinolon-6-ylglyoxal hydrate obtd by method F (AcOH) from 50. kCrude 1-allyl-4-quinolon-6-ylglyoxal hydrate obtd by method F (AcOH) from 51. Crude 1-n-butyl-4-quinolon-6-ylglyoxal hydrate obtd by method F (AcOH) from 52. mCrude 1-methyl-4-quinolon-7-ylglyoxal hydrate obtd by method F (AcOH) from 53. nCrude 2,3-dihydrobenzofuran-5-ylglyoxal obtd by method F (dioxane) from 2,3-dihydrobenzofuran-5-yl methyl ketone [G. Baddeley and M. A. Vickars, J. Chem. Soc., 4665 (1958)]. ^oCrude 2-methyl-2,3-dihydrobenzofuran-5-viglyoxal obtd by method F (dioxane) from methyl 2-methyl-2,3-dihydrobenzofuran-5-yl ketone (ref in footnote n). No attempt was made to sep geometric isomers. PC: calcd, 64.3; found, 63.8. ⁴Crude chroman-6-viglyoxal obtd by method F (dioxane) from chroman-6-yl methyl ketone [G, Chatelus, Ann. Chim. (Paris), 4, 505 (1949)]. ⁴Crude dibenzofuran-2-ylglyoxal obtd by method F (dioxane) from dibenzofuran-2-yl methyl ketone [P. Galewski, Justus Liebigs Ann. Chem., 264, 187 (1891)]. Scrude N-isopropyl-1,3-dimethylindol-2-ylglyoxylamide obtd by method H from 1,3-dimethylindole [J. Meisenheimer, L. Angermann, O. Finn, and E. Vieweg, Ber., 57, 1744 (1924)]. ^tCrude N-isopropyl-1-methylindol-2-ylglyoxylamide obtd by method H from 1-methylindole [K. T. Potts and J. E. Saxton, Org. Synth., 40, 68 (1960)]. Literature on 20 gives mp 114.5-115.5° (ref 6). "C: calcd, 55.4; found, 54.7. H: calcd, 6.5; found, 6.0. "2-Bromo-1-(3-methylquinoxalin-2-vi)ethanol obtd by NaBH, reduction of 73 was not characterized, "Benzofuran-2-ylglyoxal [S. Fatutta, Gazz, Chim, Ital., 89, 1598 (1959)]. *2-Chloro-1-(2,3-dihydrobenzofuran-2-yl)ethanol [D. Misiti, A. Amato, and V. Rosnati, ibid. 93, 1128 (1963)]; chloromethyl 2.3-dihydrobenzofuran-2-yl ketone [V, Rosnati, F, De Marchi, D, Misiti, and C, Francescaglia, ibid., 94, 979 (1964)]. ^yNo anal. τ (CDCl₂), 2.6-3.3 (multiplet, Ar H, 4), 5.35 (multiplet, H at C_2 , 1), 6.25 (multiplet, CH(OH), 1), 6.75 (doublet, H's at C_3 , 2), 7.0–7.5 (multiplet, CH₂NHCH<, 3), 7.54 (singlet, OH and NH, 2), 8.9 (doublet, CH(CH₃)₂, 6). The spectrum of 36A had signals at 5.25, 6.8, and 7.65 in place of those at 5.35, 6.75, and 7.54; the shape of the multiplets for H at C_2 and CH(OH) differed for 36A and 36B, but no stereochem assignments were possible. ²1,3-Benzodioxole-2-carbonyl chloride²⁰ was converted to 1,3-benzodioxol-2-yl diazomethyl ketone by the method given for 77. Treatment of the diazomethyl ketone with HBr gave the bromomethyl ketone which was reduced by NaBH₄ to give crude 2-bromo-1-(1,3-benzodioxol-2-yl)ethanol (see Experimental Section). aaCrude 2-bromo-1-(2-thienyl)ethanol was obtd by NaBH₄ reduction (as in footnote z) of bromomethyl 2-thienyl ketone [H. Brunswig, Ber, 19, 2890 (1886)]. bbH: calcd, 7.0; found, 7.5.

| R |
|------------|
| |
| NR |
| |
| - |
| <u> </u> |
| E 1 |
| <u></u> |
| - |
| <u></u> |
| - |
| 0 |
| <u> </u> |
| H |
| 5 |
| \cup |
| |
| ~ |
| _ |
| |
| • |
| ÷. |
| |
| |
| പ |
| - |
| - |
| _ |
| |
| |

| Compound | R | R¹ | R ² | Method ^a | Form | Crystn solvent ^b | Mp, °C | Formula | Analyses | Infusion rate, μg/kg per min | % change in heart rate | % inhibition of tachycardia |
|---|-------------------------|--|---|---------------------------------|--------------------------------|--|--|--|----------------------------|---------------------------------|---------------------------|--------------------------------|
| 6 | As 17 | CH ₃ | CH(CH ₃) ₂ | С | HCI | MeOH + EtOAc | 198-199 | C ₁₃ H ₂₀ CINO ₃ | C, H, Cl, N | 100 | +21 | 68 |
| 41 | As 19 | Ŧ | Н | С | Base hy- | EtOAc | 82-83 | C ₁₀ H ₁₃ NO ₃ · H ₂ O | C, H, N | 250 | -12 | 25 |
| 42 | As 19 | Н | C(CH ₃),CH ₃ OH | Α | Base | EtOAc | 101-102 | C. H. NO. | C. H. N | 100 | +8 | 85 |
| 43 | As 19 | Н | CH(CH ₁)(CH ₂) ₂ C ₆ H ₅ | See Exptl | HCI | MeOH + EtOAc | 158-159 | C, H, CINO, | H. Cl. N: C ^c | 100 | +22 | 94 |
| 44 | As 24 | Н | C(CH,), C(CH,) | B | Base | EtOAc | 124-126 | C.H.NO | H N Cq | 100 | ^ | 85 |
| 45 | As 24 | Н | C(CH,),CH,OH | \mathbf{B}^{e} | Picrate | Me,CO | 146 | CHN.O. | C.H.N | • | +14 | 55 |
| 46 | As 24 | Н | (CH,),N(CH,), | B | Oxalate | EtÓH + H,O | 128-130dec | C.H.N.O. | C.H.N | 250 | 71- | x |
| 47 | As 27 | CH ₃ CH ₃ | CH ₂ CH ₃ | B | Base | P(40) | 62-64 | - | C, H, N | 108 | Not | Not active |
| ^a Methods . indol-3-ylgly | refer to E. oxylamid | ^{<i>a</i>} Methods refer to Experimental Section. ^{<i>b</i>} Pl indol-3-ylglyoxylamide was prepd by method 1 | Methods refer to Experimental Section. $^{b}P(40)$ stands for petroleum ether bp 4 to 1-3-ylglyoxylamide was prepd by method H. $^{f}Administered$ intraduodenally, 1 | or petroleum e ered intraduo | other bp 40–6 denally, 10 m | $40-60^{\circ}$. ^c C: calcd, 66.0; found, 65.5. ^d C: calcd, 73.2; found, 72.6. ^e Crude N-2-hydroxy-1,1-dimethylethyl-1-methyl-10 mg/kg. ^g Administered sc in the rat, 10 mg/kg. | found, 65.5. ⁶ sc in the rat, | ^I C: calcd, 73.2; foun 10 mg/kg. | d, 72.6. ^e Cruc | ie N.2-hydroxy-1 | ,1-dimethylethy | l-1-methyl- |



Other intermediates which were characterized are given in Table III. The intermediate glyoxals were prepared by oxidation of a methyl ketone with SeO_2 in the solvent specified (method F) or by treatment of a bromomethyl ketone with DMSO (method G).⁵ The glyoxylamide intermediates 64-70 were prepared by the action of $(COCl)_2$ on the appropriate indole, followed by treatment with an amine (method H).⁶ Bromomethyl ketones were obtained by brominating methyl ketones in the solvent specified (method I). Substituted aminomethyl ketones were prepared by the action of an amine on a bromomethyl ketone (method J); the hexamine route gave unsubstituted aminomethyl ketones (method K).⁵ The N-alkylquinolin-4-ones 49-53 were obtained by the action of a dialkyl sulfate (method L) or an alkyl halide (method M) on the appropriate 4-hydroxyquinoline derivative. The diazo ketone 77 was made by the route



The orientation of the acid 75 is based on nmr evidence. Had the CO₂H been at C₂, then the H at C₂ signal (H_B of an ABX system) would have been expected at lower field than H_A and H_X. Attempts to detosylate the ester 74 with H₂SO₄ failed; water-soluble derivatives were formed, presumably by sulfonation. With Na in NH₃,⁹ the ester was degraded to *o*-aminophenol in good yield.

One compd, 86, in which C-1 of an ethanolamine side chain attached to benzene forms part of the heterocyclic system, was prepared by treating *N*-methylisatin with dimethyloxosulfonium methylide⁷ to give the oxirane 85 which with *i*-PrNH₂ gave 86.

The diasteroisomers 36A and 36B were separated by fractional crystallization. No attempt was made to separate the diastereoisomers corresponding to 16, 31, 34, and 43.

Biological Results. The results of the biological screening tests[§] are given in Tables I and II. β -Adrenergic blocking potency was determined in the usual way.


 $^{^{\$}}$ Biological testing was carried out by Drs. J. W. Black and R. G. Shanks and Mr. D. Dunlop. For further information see ref 10.

| T-1-1- | TTT | RCOX |
|--------|-----|------|
| | | |
| | | |


0

| Com- pound | R | х | Method ^a | Crystn solvent ^b | Mp,°C | Formula | Analyses |
|---------------|-------------------------------|--|----------------------------------|-------------------------------|--------------|---|--------------------------|
| 48 | As 7 | СНО | F(AcOH) ^c | H ₂ O | 145 | $C_{11}H_7NO_2 \cdot H_2O$ | N |
| 49 | As 9 | CH, | Lď | PhCl | 184 | $C_{12}H_{11}NO_2$ | Ν |
| 50 | As 10 | CH ₃ | L^{d} | BuOH | 156-158 | $C_{13}H_{13}NO_{2}$ | Ν |
| 51 | As 11 | CH ₃ | M^d | H,O | 166 | $C_{14}H_{13}NO_2 = 0.25H_2O$ | C, H, N |
| 52 | As 12 | CH ₃ | M^d | CĆI₄ | 126-128 | $C_{15}H_{17}NO_{2}$ | H, N, C^e |
| 53 | As 13 | CH ₃ | Ľ | PhCi | 178 | $C_{12}H_{11}NO_{2}$ | C, H, N |
| 54 | ОН | CH3 | g | DMF | 280 | C11H°NO5 | C, H, N |
| | N [×] N [×] | | _ | | | | |
| 55 | As 17 | CH ₂ NH- <i>i</i> -Pr · HCl | J ^h | MeOH + EtOAc | 227-228 | C ₁₂ H ₁₆ CINO ₃ | C, H, Cl, N |
| 56 | As 17 | CH ₂ NMe- <i>i</i> ·Pr · HCl | J ^h | MeOH + EtOAc | 180-181 | $C_{13}H_{18}CINO_3$ | C, H, Cl, N |
| 57 | As 19 | CH ₂ NH- <i>i</i> -Pr · HCl | J ⁱ . | EtOH-Et ₂ O | 204-205 | $C_{13}H_{18}CINO_3$ | C, H, N |
| 58 | As 19 | CH ₂ NH ₂ · HCl | K ⁱ | EtOH-H ₂ O | 248 | $C_{10}H_{12}CINO_3$ | C, H, Cl, N |
| 59 | As 19 | CHŌ | G^i | H ₂ O | 99-103 dec | $C_{10}H_{8}O_{4} \cdot H_{2}O$ | С, Н |
| 60 | As 19 | CH,Br | I(CS ₂) ^j | C ₆ H ₆ | 119-120 | C ₁₀ H ₉ BrO ₃ | C, H, Br |
| 61 | As 20 | CH,NH-i-Pr · HCl | J | EťOH + Et₂O | 204-205 | C ₁₄ H ₂₀ CINO ₃ | C, H, Cl, N |
| 62 | As 20 | CH ₂ Br | $I(CS_2)$ | $C_{6}H_{6} + P(40)$ | 75-76 | $C_{11}H_{11}BrO_3$ | C, H, Br |
| 63 | As 20 | CH, | See Exptl | 0 0 0 | 120 (0.5 mm) | $C_{11}H_{12}O_{3}$ | С, Н |
| 64 | As 24 | CONH- <i>tert</i> -Bu | \mathbf{H}^{k} | EtOH | 143 | $C_{15}H_{18}N_{2}O_{2}$ | C, H; N ^l |
| 65 | As 24 | CONH(CH ₂) ₃ NMe ₂ | \mathbf{H}^{k} | Cyclohexane | 83 | $C_{16}H_{21}N_{3}O_{2}$ | C, H, N |
| 6 6 | As 25 | CONH-i-Pr | Н ^{<i>т</i>} | P(80) | 96 | $C_{15}H_{18}N_{2}O_{2}$ | H, N; C ⁿ |
| 67 | As 26 | CONH- <i>i</i> -Pr | Н ^о | EtOH | 196-198 | $C_{17}H_{22}N_2O_2$ | C, H, N |
| 68 | As 27 | CONH- <i>i</i> -Pr | Н ^р | P(100) | 132-134 | $C_{20}H_{20}N_{2}O_{2}$ | C, H, N |
| 69 | As 27 | CONEt ₂ | H ^p | P(100) | 93 | $C_{21}H_{22}N_2O_2$ | C, H, N |
| 70 | As 28 | CONH-i-Pr | H^{q} | EtOH | 181-183 | $C_{20}H_{20}N_{2}O_{2}$ | C, H, N |
| 71 | As 29 | CH ₂ NH ₂ ·HBr | K ^r | EtOH + H ₂ O | 284 | $C_{12}H_{13}BrN_{2}O_{2} \cdot 0.5H_{2}O$ | C, H, Br, N |
| 7 2 | As 32 | CH,Br | I (48% HBr) ^s | MeOH + H,O | 116-117 | C ₁₀ H ₇ BrN ₂ Ô | C, H, N |
| 73 | As 33 | CH,Br | $1(HBr)^{t}$ | MeOH + H,O | 107 | $C_{11}H_{9}BrN_{2}O$ | C, H, N; Br ^u |
| 74 | As 34 | OEt | See Exptl | MeOH | 135-136 | C ₁₈ H ₁₉ NO₅S | C, H, N, S |
| 75 | As 34 | ОН | See Exptl | MeOH + EtOAc | 181-182 | C ₁₆ H ₁₅ NO ₅ S | C, H, N, S |
| 76 | As 34 | Cl | See Exptl | P(60) | 103-104 | C ₁₆ H ₁₄ CINO ₄ S | C, H, CI, N, S |
| 77 | As 34 | CHN ₂ | See Exptl | Et,O | 132-134 | C ₁₇ H ₁₅ N ₃ O ₄ S | C, H, N, S |
| 78 | As 39 | сно | $F (dioxane)^{\nu}$ | Moist CHCl ₃ | 128-130 | $C_{10}H_8O_2S \cdot H_2O$ | С, Н |

^aMethods refer to the Experimental Section. ^bP(40) etc. see footnote b of Table I. ^cQuinolin-6-yl methyl ketone [S. G. Waley, J. Chem. Soc., 2008 (1948)]. ^d4-Hydroxyquinolin-6-yl methyl ketone (footnote g, Table I). ^eC: calcd, 74.0; found, 73.4. ^fPrepd from **54**. ^gPrepd from 3-aminoacetophenone by the method of Riegel, *et al.*, ref 19. ^hBromomethyl 3,4-methylenedioxyphenyl ketone [N. L. Drake and W. B. Tuemmler, J. Amer. Chem. Soc., 77, 1204 (1955)]. ⁱPrepd from compound 60. ^j1,4-Benzodioxan-6-yl methyl ketone [J. J. Denton, R. J. Turner, W. B. Neier, V. A. Lawson, and H. P. Schedl, J. Amer. Chem. Soc., 71, 2048 (1949)]. ^k1-Methylindole [K. T. Potts and J. E. Saxton, Org. Syn., 40, 68 (1960)]. ^lN: calcd, 10.9; found, 10.4. ^m1-Ethylindole [A. Michaelis, Ber., 30, 2809 (1897)]. ⁿC: calcd, 69.8; found, 69.3. ^o1-n-Butylindole [J. v. Braun and O. Bayer, Ber., 58, 387 (1925)]. ^p1-Benzylindole [H. Plieninger, *ibid.*, 87, 127 (1954)]. ^q2-Benzyl-1- methyllandole [A. F. Ames, D. E. Ames, C. R. Coyne, T. F. Grey, I. M. Lockhart, and R. S. Ralph, J. Chem. Soc., 31, 951 (1954)]. ^sMethyl quinoxalin-2-yl ketone [G. Henseke and K. J. Bähner, Ber., 91, 1605 (1958)]. ^tMethyl 3-methylquinoxalin-2-yl ketone [F. Sachs and A. Röhmer, *ibid.*, 35, 3307 (1902)]. ^uBr: calcd, 30.2; found, 29.7. ^vBenzo[b]thiophen-3-yl methyl ketone [M. W. Farrar and R. Levine, J. Amer. Chem. Soc., 72, 4433 (1950)].



It is clear from Table I that the naphthalene ring of pronethalol can be replaced by many heterocyclic ring systems to give compds which have the pronethalol level of potency, *e.g.*, 8, 10, 11, 15, 17, 18, 23, 24, 25, 30, and 39. Pronethalol infused at 50 μ g/kg per min produces a 45% inhibition of isoproterenol-induced tachycardia in the cat.⁵ A few compds showed a slightly higher potency, *i.e.*, 9, 19, and 32. The level of potency of 15, 17, 18, 19, and 39 was as expected, because the group replacing naphthalene was about the same size and without functionality. The 4 most potent compds, 35, 36A, 36B, and 37, which were from 5 to 10 times more potent than pronethalol, all contained those features of the propranolol type (87) common to the highly potent 1,4-benzodioxan and chroman analogs described in part 7.¹ That the 1,4-benzodioxan and chroman ring systems are not responsible *per se* follows from a comparison of 18 and 19 with 2 and 1 (this paper). Compd 2 is the same as 5 (in part 7, 5 μ g/kg per min, 32% inhib) and 1 corresponds with the geometric isomers 3 or 4 (in part 7, 1 and 1 μ g/kg per min, 80 and 36% inhib, respectively). As in the



1,4-benzodioxan series,¹ there was no marked difference in potency between the geometric isomers **36A** and **36B**.

At the other end of the scale the absence of or low potencies of 14, 26, 27, 28, and 34 suggest once more that the group replacing naphthalene can be made too large. This has previously been commented upon for the phenanthrene and anthracene analogs in part 4,¹¹ and for the naphthol [2,3b]-1,4-dioxane analogs in part 7.¹ The low potencies of 13, 22, and 29 cannot be so explained.

Changes made to the substituent on the side chain nitrogen (Table II) followed the expected pattern. The tertiary amine 40 and the primary amine 41 were less potent than the corresponding secondary amines 17 and 19.^{5,11} Replacement of *i*-Pr by *tert*-Bu retained potency (44 and 24), by 2-hydroxy-1,1-dimethylethyl slightly lowered potency (42 and 19), and by 3-dimethylaminopropyl virtually eliminated β -blocking activity altogether (46 and 24).⁵

A few compds, 17, 30, 31, 35, 40, and 43, caused a marked tachycardia, which tends to exaggerate the observed degree of β blockade.

Biological results on 17 and 19 in the dog have been reported by Marchetti, *et al.*¹² Compd 19 had activity similar to that of pronethalol, but 17 had very low activity.

Experimental Section

Methods A-M are representative for compds reported in the tables. Melting points and recrystg solvents given in the tables are usually not repeated in the text. Hydrogenations were carried out at room temp and atm pressure, unless stated otherwise.

A. 1-(1,4-Benzodioxan-6-yl)-2-(2-hydroxy-1,1-dimethylethylamino)ethanol (42). NaBH₄ (0.6 g, 0.016 mole) was added during 30 min to a stirred soln of 59·H₂O (1.3 g, 0.006 mole) and 2-amino-2-methylpropanol (1.2 g, 0.014 mole) in MeOH (30 ml) at 0°. The mixt was stirred at 0° for 2 hr and then the solvent was evapd *in vacuo*. HCl (0.5 N. 100 ml) was added, and then the mixt was washed with Et₂O. NaOH (4 N, 20 ml) was added to the aq acidic soln and then the product (42) was isolated by Et₂O extn.

B. 1-(N-Benzylindol-3-yl)-2-isopropylaminoethanol (27). A soln of 68 (9.3 g, 0.029 mole) in THF (150 ml) was added during 30 min to a stirred suspension of LiAlH₄ (5 g, 0.13 mole) in THF (150 ml). The mixt was heated under reflux for 2 hr and then 200 ml of solvent was evapd. The mixt was cooled, and wet Et₂O (200 ml) was cautiously added, followed by NaOH (2 N, 20 ml). The mixt was shaken and the filtered, and the filtrate was sepd. The Et₂O soln yielded 27.

l-(Indol-3-yl)-2-isopropylaminoethanol (23). Na (0.1 g, 0.0043 g-atom) was added to a stirred soln of 27 (0.5 g, 0.0016 mole) in NH_3 (100 ml). After 25 min NH_4Cl (1.5 g) was added and the NH_3 was allowed to evap. The residual solid 23 was stirred with a little H_2O to remove inorg material and then crystd.

C. 1.(3,4-Dihydro-1,5-benzodioxepin-7-yl)-2-isopropylaminoethanol (20). NaBH₄ (0.75 g, 0.02 mole) was added during 30 min to a stirred soln of 61 HCl (2 g, 0.007 mole) in MeOH (50 ml) at $0-10^{\circ}$. After 2 hr the MeOH was evapd under reduced pressure, HCl (1 N, 100 ml) was added, and the mixt was washed with Et₂O (100 ml). NaOH (10 N, 15 ml) was added to the aq acid layer, and the product (20) was isolated with Et₂O. Treatment with Et₂O-HCl gave 20 HCl.

D. 2-Isopropylamino-1-(1-methyl-4-quinolon-3-yl)ethanol (29). NaBH₄ (1.5 g, 0.04 mole) was added during 1 hr to a stirred suspension of 71 (2 g, 0.0065 mole) in Me₂CO (16 g, 0.28 mole) and MeOH (40 ml) at $5-10^{\circ}$. After 16 hr the MeOH and excess of Me₂CO were evapd. 29 was isolated (CHCl₃) in the same way as 20 (method C) and converted to the oxalate salt.

D. 1-(Benzimidazol-2-on-5-yl)-2-isopropylaminoethanol (6). A soln of crude aminomethyl benzimidazol-2-on-5-yl ketone \cdot HBr¹³ (5 g) in H₂O (300 ml) and Me₂CO (80 ml) was hydrogenated in the presence of Pt₂O (1 g). The mixt was filtered, and the filtrate was evapd to dryness to give 6·HBr.

1-(1,4-Benzodioxan-6-yl)-2-(1-methyl-3-phenylpropylamino)ethanol (43). A soln of 41 H_2O (2 g, 0.0095 mole) in 1-phenylbutan-3-one (2.25 g, 0.015 mole), EtOH (30 ml), and concd HCl (1 ml) was hydrogenated in the presence of Pt₂O (0.3 g). The mixt was filtered, and the filtrate was evapd to dryness. The residual gum was stirred with Et₂O and solid 43 HCl sepd. Ethyl *N*-*p*-Toluenesulfonylbenzomorpholine-2-carboxylate (74). Ethyl α,β -dibromopropionate (15 g, 0.0057 mole) was added to a stirred mixt of 2-*p*-toluenesulfonylaminophenol¹⁴ (50 g, 0.19 mole), anhyd K₂CO₃ (25 g), and Me₂ CO (700 ml) which was being heated under reflux. After 30 min, more K₂CO₃ (25 g) and more ester (15 g) were added. The procedure described in the last sentence was repeated twice more. After 16 hr heating the mixt was cooled and filtered, and the filtrate was evapd to remove Me₂CO. 74 remained as a solid.

N-p-Toluenesulfonylbenzomorpholine-2-carboxylic Acid (75). A soln of 74 (90 g) in NaOH (10%, 135 ml) was heated at 100° for 16 hr, cooled, acidified with concd HCl, and then extd with Et₂O. The ext gave 75: τ (TFA) 2.1-3.0 (multiplet, Ar H, 8), 5.3 (H_A = H at C₂), 5.6 (H_B = H at C₃), 6.25 (H_X = H at C₂) (ABX system, OCH₂CH(CO₂H)N, J_{AB} = 3, J_{AX} = 12. J_{BX} = 8 cps, 3), 7.54 (singlet, ArCH₃₃ 3).

N-p-Toluenesulfonylbenzomorpholine-2-carbonyl Chloride (76). 75 (15 g), SOCl₂ (150 ml), and CHCl₃ (450 ml) were heated under reflux for 16 hr. CHCl₃ and excess of SOCl₂ were evapd to leave 76 as a solid.

Diazomethyl *N*-*p*-Toluenesulfonylbenzomorpholin-3-yl Ketone (77). A slight excess of ethereal CH_2N_2 was added to a soln of 76 (13.5 g) in Et_2O (350 ml) and after 16 hr the Et_2O was evapl to leave 77 as a solid.

2-Isopropylamino-1-(N-p-toluenesulfonylbenzomorpholin-3yl)ethanol (34). A soln of 77 (1 g) in Me₂CO (8 g) and EtOH (20 ml) was hydrogenated in the presence of Pt₂O (0.3 g). The mixt was filtered, and the filtrate was evapd to dryness. The residue was shaken with HCl (1 N, 200 ml) and Et₂O (50 ml). The acidic aq soln was made alk with NaOH (2 N) and then extd with Et₂O. The ext gave 34.

Attempted Detosylation of 74. Small pieces of Na were added to a soln of 74 (3 g) in liq NH₃ until a blue color persisted for 3 min. Excess Na was destroyed with AcONH₄ and then the NH₃ was allowed to evap. H₂O was added, and the mixt was extd with EtOAc. The ext gave o-aminophenol, mp 174° (0.8 g, 89%).

2-*N*-Isopropylamino-1-(1,2,3,4-tetrahydroisoquinol-3-yl)ethanol (31) and 4,4-Dimethyl-1-hydroxy-2,3,4,6,11,11 α -hexahydro-1*H*-pyrimido [1,6-*b*] isoquinoline (80). A soln of 1-(isoquinol-3-yl)-2-nitroethanol (79)[#] (1 g) in HCl (2 N, 5 ml), H₂O (40 ml). and Me₂CO was hydrogenated at room temp and 100 atm pressure for 16 hr in the presence of Pd/C (5%, 1 g). The mixt was filtered, the filtrate was basified, and the org material (770 mg) was isolated with Et₂O. Fractional crystn from EtOAc gave 80: mp 188– 190°; τ (D₂O) 2.51 (singlet, Ar H, 4) 8.32 and 8.75 (singlets, CH₃, 3 each); m/e 232 (C₁₄H₂₀N₂O), 130 (C₉H₈N(A), 72.8*), 101 (C₅H₁₁NO (B), 43.9*), 58, Me₂C=NH₂⁺, 33.3*). Anal. (C₁₄H₂₀N₂O) C, H. N.



The mother liquors from the above crystn were evapd and the gum (in Et_2O) was treated with Et_2O -HCl. The hydrochloride was fractionally crys⁴ to give 31 · 2HCl.

E. 2-Isopropylamino-1-(2-phenothiazinyl)ethanol (14). A soln of 2-chloro-1-(2-phenothiazinyl)ethanol¹⁵ (5 g, 0.018 mole) and *i*-PrNH₂ (10 ml, 0.12 mole) in MeOH (250 ml) was heated under reflux for 66 hr and then the MeOH and excess *i*-PrNH₂ were evapd. The residue was dissolved in dil HCl, and the soln was washed with Et₂O. The aq acid soln was made alk and extd with Et₂O. The ext gave 14.

1-(1,2-Dihydro-1-methyl-2-oxo-4-quinolyl)-2-isopropylaminoethanol (30). A soln of trimethyloxosulfonium iodide⁷ (2.4 g, 0.011 mole) in DMSO (50 ml) was stirred under N₂ while a 50% mineral oil dispersion of NaH (0.52 g, 0.011 mole) was added in small portions. The mixt was stirred under N₂ at $50-60^{\circ}$ for 30 min and then a soln of 1,2-dihydro-1-methyl-2-oxoquinoline-4carbaldehyde¹⁶ (1.87 g, 0.01 mole) in DMSO (30 ml) was added. The mixt was stirred at 50-60° for 2 hr, cooled, dild with H₂O (200 ml), and extd with CHCl₃. The ext gave the intermediate oxirane as a gum. This was dissolved in EtOH (80 ml) and *i*-PrNH₂ (8 ml), and the mixt was refluxed for 3 hr. EtOH and excess *i*-PrNH₂ were evapd and then 30 was isolated in the same way as 14.

[#]Kindly donated by Dr. T. R. Gormley, Department of Chemistry, University College, Dublin.

2-(a, B-Diacetoxyvinyl)quinoxaline (83) and 2-Acetoxyacetylquinoxaline (82). A suspension of 2-(D-arabino-tetrahydroxy-butylquinoxaline⁸ (15 g) in dry $C_{s}H_{s}N$ (40 ml) was added to a soln of Na (3 g) in MeOH (40 ml), and the mixt was heated under reflux for 2 hr. The solid which sepd after 4 hr at 0° was isolated and dissolved in H₂O (100 ml), and the soln was acidified with H₂SO₄ (6 N_1 20 ml). The red solid (84) which sepd was isolated and dried. A soln of this solid (5.9 g) in C₅H₅N (18 ml) and Ac₂O (18 ml) was kept at room temp for 18 hr, poured into H₂O (200 ml), and extd 5 times with Et₂O (100 ml each time). The combined Et₂O exts were washed successively with HCl (1 N, 100 ml), satd NaHCO, soln (100 ml), and then H₂O (100 ml). The ext gave 83, mp 117° , and 82, mp 113-114°, by fractional crystn from petr ether, bp 60-80°: 83, nmr τ (CDCl₃) 1.10 (singlet, N=CCH=N, 1), 1.54 (singlet, C(OAc)=CHOAc, 1), 1.7-2.5 (multiplet, Ar H, 4), 7.57 and 7.73 (singlets, C(OCOCH₃)=CHOCOCH₃, 3 and 3); Anal. (C₁₄H₁₂N₂O₄) C, H, N; 82, nmr τ (CDCl₃), 0.50 (singlet, N=CCH=N, 1), 1.65-2.25 (multiplet, Ar H, 4), 4.25 (singlet, COCH₂OAc, 2), 7.62 (singlet, OCOCH₃, 3); Anal. ($C_{12}H_{10}N_2O_3$) C, H, N.

2-Isopropylamino-1-(2-quinoxalyl)ethanol (32). *i*-PrNH₂ (10 ml, 0.12 mole) was added during 10 min to a stirred soln of 82 (0.5 g, 0.0022 mole) in EtOH (30 ml) at 0° ; 5 min later a soln of NaBH₄ (1 g, 0.027 mole) in EtOH (10 ml) was added. After 1 hr glac AcOH (15 ml) was added slowly, followed by H₂O (100 ml) and HCl (6 N, 5 ml). The EtOH was evapd, and the residual aq soln was washed 3 times with Et₂O. The aq soln was made alk with NaOH (6 N, 20 ml) and extd with Et₂O. The ext gave 32. In a similar way (MeOH soln) 32 was obtd from 83.

F. Quinolin-6-ylglyoxal Hydrate (48). Methyl 6-quinolyl ketone¹⁷ (3.4 g, 0.02 mole), SeO₂ (2.26 g, 0.02 mole), and AcOH (80%, v/v, 20 ml) were heated at 90° for 4 hr. The mixt was filtered and the filtrate was evapd to dryness. The residual gum was stirred with NaHCO₃ (2%, 100 ml), and the solid 48 which sepd was isolated.

G. 1,4-Benzodioxan-6-yigiyoxal Hydrate (59). A soln of 60 (10 g) in DMSO (80 ml) was kept at room temp for 3 days and then poured onto ice; 59 was isolated by Et₂O extn.

H. N-Isopropyl-1-benzylindole-3-ylglyoxylamide (68). A soln of 1-benzylindole (26 g, 0.125 mole) in Et_2O (200 ml) was added during 1 hr to a stirred soln of (COCl)₂ (9 ml, 0.105 mole) in Et_2O (100 ml) at 5°. After 30 min a soln of *i*-PrNH₂ (31 ml, 0.37 mole) in Et_2O (200 ml) was added. After 16 hr the mixt was filtered, the solid was stirred with NaOH (4 N, 100 ml) and then filtered. The solid 68 was recrystd.

3,4-Dihydro-1,5-benzodioxepin-7-yl Methyl Ketone (63). A soln of 3,4-dihydro-1,5-benzodioxepine¹⁸ (20 g, 0.133 mole) and AcCl (11 g, 0.14 mole) in CS₂ (60 g) was added during 1 hr to a stirred mixt of AlCl₃ (26 g, 0.2 mole) and CS₂ (80 g) at 10–15°. After 2 days the mixt was poured onto ice. The CS₂ phase was sepd, and the aq phase was extd with Et₂O. The combined CS₂– Et₂O solns were washed with NaOH (2 N, 50 ml), dried (MgSO₄), and distd to give 63, bp 120° (0.5 mm).

I. Bromomethyl 3,4-Dihydro-1,5-benzodioxepin-7-yl Ketone (62). Br₂ (9.6 g, 0.06 mole) was added during 30 min to a stirred soln of 63 (11.4 g, 0.06 mole) in CS_2 (135 ml) at 0°. After 2 hr the CS_2 was evapd and the residual 62 recrystd.

J. 3,4-Dihydro-1,5-benzodioxepin-7-yl Isopropylaminomethyl Ketone (61). *i*-PrNH₂ (4 g, 0.068 mole) was added to a soln of 62 (7.6 g, 0.028 mole) in Et₂O (200 ml) at 0°. After 2 hr the mixt was filtered, and the filtrate was evapd. HCl (1 N, 100 ml) was added, and the mixt was washed with Et₂O (100 ml). NaOH (8 N, 20 ml) was added to the aq acid soln. The product (61) was isolated by Et₂O extn and converted to $61 \cdot$ HCl with Et₂O-HCl.

K. Aminomethyl 1,4-Benzodioxan-6-yl Ketone (58). A soln of hexamine (6 g, 0.043 mole) in CHCl_3 (100 ml) was added to a soln of 60 (10 g, 0.039 mole) in CHCl_3 (100 ml), and the mixt was shaken for 30 min. The hexaminium salt was isolated and shaken with EtOH (250 ml) and concd HCl (15 ml) at room temp for 3 days; 58 \cdot HCl sepd as a solid.

L. 1-Methylquinol-4-on-6-yl Methyl Ketone (49). 4-Hydroxyquinol-6-yl methyl ketone (30 g), aq NaOH (40% w/v, 100 ml), and H_2O (400 ml) were stirred vigorously while Me₂SO₄ (40 ml) was added. The mixt was stirred for 2 hr and then extd with CHCl₃ (4 times, 100 ml each time). The ext was washed with H_2O , dried (MgSO₄), and then evapd to give 49.

M. 1-Allylquinol-4-on-6-yl Methyl Ketone (51). 4-Hydroxyquinol-6-yl methyl ketone¹⁹ (5.4 g, 0.029 mole) was dissolved in a soln of Na (0.7 g, 0.03 g-atom) in EtOH (50 ml) and then allyl bromide (6.3 g, 0.052 mole) was added. The soln was heated under reflux for 16 hr and then evapd to dryness. The residue was extd with C₆H₅Cl. Petr ether (bp 40-60°) was added to the ext to ppt 51, which was then recrystd from H₂O.

1-(1,3-Benzodioxol-2-yl)-2-bromoethanol. A soln of 1,3-benzodioxol-2-carbonyl chloride²⁰ (5 g) in Et₂O (50 ml) was added to a soln of CH₂N₂ (6.5 g) in Et₂O (180 ml) at -10° , and then the soln was allowed to warm to room temp. After 64 hr the solvent was evapd to give crude 1,3-benzodioxol-2-yl diazomethyl ketone which was dissolved in Et₂O (100 ml), cooled to -5° , and treated with aq HBr (S.G. 1.46, 5 ml). The mixt was stirred for 1 hr and then evapd to dryness under reduced pressure to give crude 1,3-benzodioxol-2-yl bromomethyl ketone. This (2.2 g) was dissolved in EtOH (15 ml), cooled to 0°, and then NaBH₄ (0.5 g) was added during 30 min. After 2 hr the mixt was added to ice (50 g) and HCl (11 N, 5 ml). Extn with EtOAc gave crude 1-(1,3-benzodioxol-2-yl)-2-bromoethanol.

Acknowledgments. We thank Dr. T. W. Thompson for preparing compounds 36A and 36B, and Dr. A. G. McGregor and Mr. H. Gallagher for compound 33. We also thank Dr. G. Bedford and Mr. M. J. Rix for discussions on nmr and mass spectra.

References

- (1) R. Howe, B. S. Rao, and M. S. Chodnekar, J. Med. Chem., 13, 169 (1970).
- (2) W. Hepworth, A. Mitchell, M. S. Chodnekar, and R. Howe, British Patent 1,013,224 (1965).
- (3) R. P. Slatcher, British Patent 1,019,225 (1966).
- (4) L. H. Smith, British Patent 1,135,340 (1968).
- (5) R. Howe, A. F. Crowther, J. S. Stephenson, B. S. Rao, and L. H. Smith, J. Med. Chem., 11, 1000 (1968).
- (6) The Upjohn Company, British Patent 797,258 (1958).
- (7) E. J. Corey and M. Chaykovsky, J. Amer. Chem. Soc., 84, 867 (1962).
- (8) K. Maurer and B. Boettger, Ber., 71, 1383 (1938).
- (9) J. M. Swan and V. Du Vigneaud, J. Amer. Chem. Soc., 76, 3110 (1954).
- (10) J. W. Black, W. A. M. Duncan, and R. G. Shanks, Brit. J. Pharmacol., 25, 577 (1965).
- (11) R. Howe, B. J. McLoughlin, B. S. Rao, L. H. Smith, and M. S. Chodnekar, J. Med. Chem., 12, 452 (1969).
- (12) G. Marchetti, L. Merlo, and V. Noseda, Arzneim.-Forsch., 18, 43 (1968).
- (13) J. R. Vaughan, Jr., and J. Blodinger, J. Amer. Chem. Soc., 77, 5757 (1955).
- (14) L. F. Hewitt, H. King, and W. O. Murch, J. Chem. Soc., 1355 (1926).
- (15) A. Burger and J. B. Clements, J. Org. Chem., 19, 1113 (1954).
- (16) D. J. Cook and M. Stamper, J. Amer. Chem. Soc., 69, 1467
- (1947). (17) S. G. Waley, J. Chem. Soc., 2008 (1948).
- (17) S. G. Waley, J. Chem. Soc., 2008 (1948). (18) R. B. Thompson, U. S. Patent 2,698,329 (1954).
- (19) B. Riegel, G. R. Lappin, B. H. Adelson, R. I. Jackson, C. J. Albisetti, R. M. Dodson, and R. H. Baker, J. Amer. Chem. Soc., 68, 1264 (1946).
- (20) J. N. Gardner and G. L. Willey, U. S. Patent 3,149,128 (1964).